Drugs / HRS-9190
last change Jul 2026 re-read 2 minutes ago

HRS-9190

also known as [14C] HRS-9190
Investigated by
Jiangsu HengRui Medicine Co., Ltd.

Trials 5 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT07494175 Apr → May 2026 overdue Jiangsu HengRui Medicine Co., Ltd. Active not recruiting No outcome recorded
Phase 1 NCT07142850 Aug → Oct 2025 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT06932315 Apr → Aug 2025 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 22 trials
Phase 2 NCT07446309 Apr → Jul 2026 overdue Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT07404579 Mar → May 2026 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT07252921 Comparator Oct → Dec 2025 Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as HRS-9190 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07142850
5

NCT07252921

NCT07494175

NCT06932315

NCT07404579

NCT07446309

Known as [14C] HRS-9190 “\[14C\] HRS-9190 for injection” NCT07494175
Route Intravenous “after intravenous bolus injection and continuous intravenous infusion” NCT07142850